Healthcare Business

Biotechnology word cloud

RBC Has 4 Biotech Stocks to Buy After Massive Pullback

The XBI, which is the S&P 500 biotech index, has been hit hard this week and is down almost 14% since last Friday. While still up big over the past ...
Read Full Story »
health care

UBS Raises Price Targets on 4 Top Health Care Providers

If there has been one group stocks that has delivered for investors this year it has been the managed care organizations (MCO) that are the top health care providers in ...
Read Full Story »
research

Major Biotech Is So-So for Short Sellers

The short interest data are out for the March 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
investor research

Why Deutsche Bank Says to Buy Gilead and Vertex Pullbacks

There are two events in the biotech world that can quickly bring down the price of a stock. One is to have a failed or, sometimes worse, a misunderstood clinical ...
Read Full Story »
buy sell

Can MEI Pharma Survive?

Biotech and pharmaceutical companies live and die by the sword of innovation, or specifically, by clinical trials that test new drug candidates. A successful trial can mean a boom in ...
Read Full Story »
Biotechnology word cloud

The Top 5 Biotech Stocks of 2015 — Average Gains So Far Over 200%

The multiyear run in major biotech stocks has not let up in 2015. Most of the large and mid-cap stocks in the industry are higher, but the smaller and lesser ...
Read Full Story »
generic drugs

4 Pharmaceutical Stocks to Buy for Outperformance in 2015

It is a nice change sometimes when the prognosticators on Wall Street, who tend to follow each other's lead, are not only right, but investors come out on top. Almost ...
Read Full Story »
152498601

Alzheimer’s Drug Could Be Instant Blockbuster for Biogen Idec

Over 5 million Americans are currently living with Alzheimer’s disease, and it is the sixth leading cause of death in the United States, according to the Alzheimer’s Association. Alzheimer’s, along ...
Read Full Story »
health care

How Large Is Prothena’s Market Opportunity?

Parkinson’s disease is a degenerative disorder that affects 50,000 to 60,000 new cases every year. There may even be 7 million to 10 million people living with this disease worldwide. ...
Read Full Story »
ten dollar bills

How the Tekmira Secondary Offering Could Help the Company

The Ebola scare is back but maybe not in the sense of the actual disease. Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), one of the top names in the Ebola drug arena, is ...
Read Full Story »
Euro

How the Weaker Euro Is Impacting Biotech Earnings

It is no secret that a strong dollar and a weak euro, and foreign currency environment, are acting to hurt U.S. corporate earnings. Many investors might think that biotech earnings ...
Read Full Story »
generic drugs

As Valeant Ups Salix Buyout, Will Endo Come Back?

Monday morning, Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and Valeant Pharmaceuticals International Inc. (NYSE: VRX) both announced that they had entered into an agreement on their plan to merge based on ...
Read Full Story »
DNA

3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week

One thing that can always drive a biotech stock higher is positive clinical data, and this week some big-time biotech companies could have some very import clinical data releases. A ...
Read Full Story »
generic drugs

Par Pharma Files for IPO

Par Pharmaceutical Holdings Inc. filed its Form S-1 Friday with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the number ...
Read Full Story »
payoff

Salix Now Has 2 Merger Dance Partners

The merger situation around Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) just became much more complicated. Endo International PLC (NASDAQ: ENDP) has made a bid for Salix in a private letter sent to ...
Read Full Story »